A 58-year-old male with bipolar II disorder stabilized on lamotrigine 200 mg daily and a history of diabetic peripheral neuropathy was started on pregabalin 75 mg twice daily eight weeks ago for burning neuropathic pain in both feet rated 8 out of 10 on a visual analog scale. The dose was titrated to 150 mg twice daily at week four. At today's evaluation, his pain has decreased to 5 out of 10, and he reports reduced burning and electric shock sensations. However, he describes new cognitive symptoms including word-finding difficulty, mental fogginess, and trouble concentrating at work. His PHQ-9 is 6, unchanged from before pregabalin initiation, and his mood cycling has remained stable on lamotrigine. His wife notes he seems sedated in the evenings and has had two episodes of stumbling on stairs. Renal function shows a creatinine clearance of 62 mL/min. The PMHNP is evaluating the risk-benefit balance of pregabalin in this clinical context. Which of the following best represents the appropriate evaluation?